Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of TORC1 signaling. [GO_REF:0000058, GOC:TermGenie]
The Target of Rapamycin Complex 1 (TORC1) is a central regulator of cell growth, metabolism, and survival. Its activity is tightly regulated by a variety of signaling pathways, including nutrient availability, growth factor signaling, and stress. Here's a detailed breakdown of the regulation of TORC1 signaling:
**1. Nutrient Sensing:**
* **Amino Acid Availability:** The most potent activator of TORC1 is the presence of amino acids, particularly leucine. This is mediated by the Rag GTPases, which act as sensors of amino acid levels. When amino acids are present, Rag GTPases become activated and bind to the lysosomal surface, facilitating the recruitment of TORC1 to the lysosome, where it encounters its activating substrates.
* **Glucose Availability:** Glucose is also a crucial nutrient that regulates TORC1. Glucose metabolism generates ATP, which is required for TORC1 activation. Additionally, glucose promotes the production of the mTORC1 activator Rheb, a small GTPase that is essential for TORC1 activation.
* **Energy Status:** AMPK (AMP-activated protein kinase) is a crucial energy sensor that inhibits TORC1 under conditions of energy depletion. AMPK activates tuberous sclerosis complex (TSC2) by phosphorylation, which in turn inhibits Rheb, leading to the suppression of TORC1.
**2. Growth Factor Signaling:**
* **Insulin/IGF-1 Pathway:** Insulin and insulin-like growth factor 1 (IGF-1) activate the PI3K/Akt/mTORC1 pathway. This pathway involves the activation of PI3K (phosphoinositide 3-kinase), which then activates Akt (protein kinase B). Akt inhibits the TSC1/TSC2 complex, thereby promoting Rheb activation and TORC1 signaling.
**3. Stress Responses:**
* **Hypoxia:** Hypoxia (low oxygen) inhibits TORC1 activity. Hypoxia-inducible factor 1 (HIF-1) is a key regulator of cellular responses to hypoxia, and it can suppress TORC1 by promoting the expression of REDD1, which inhibits Rheb.
* **Stress Hormones:** Stress hormones, such as cortisol, can inhibit TORC1 activity. This inhibition may be mediated through the activation of AMPK, which, as mentioned earlier, inhibits TORC1.
* **Cellular Damage:** Cellular damage, such as DNA damage, can also inhibit TORC1 signaling. This inhibition is often mediated by the activation of p53, a tumor suppressor protein that can directly inhibit TORC1 or indirectly by promoting the expression of TSC2.
**4. Negative Feedback Loops:**
* **TORC1 itself** is a negative regulator of its own activity. TORC1 activates the translation of 4E-BP1, which then inhibits the translation of mTOR, thus creating a feedback loop that limits TORC1 activity.
* **S6K1:** Another downstream target of TORC1, S6K1, is involved in negative feedback loops. S6K1 inhibits the insulin receptor substrate 1 (IRS1), which is required for insulin signaling. This feedback loop limits the sustained activation of TORC1 by insulin.
**In summary, TORC1 activity is tightly regulated by a complex network of signaling pathways that respond to nutrient availability, growth factor signaling, and stress conditions. This intricate regulation ensures that TORC1 signaling is appropriately activated under favorable conditions and suppressed under unfavorable conditions.**'
"
Protein | Definition | Taxonomy |
---|---|---|
Dual specificity tyrosine-phosphorylation-regulated kinase 3 | A dual specificity tyrosine-phosphorylation-regulated kinase 3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O43781] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
staurosporine | indolocarbazole alkaloid; organic heterooctacyclic compound | apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector | |
cyc 202 | seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors. | 2,6-diaminopurines | antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor |
harmine | harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7. Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's. | harmala alkaloid | anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite |
leucettamine b | leucettamine B: a protein kinase inhibitor isolated from the marine sponge Leucetta microraphis; structure in first source | ||
cgp 57380 | CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1 | pyrazolopyrimidine | |
((5z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4h-imidazol-4-one) | leucettine L41 : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a (2-anilino-5-oxo-1,5-dihydro-4H-imidazol-4-ylidene)methyl group at position 5. It is an inhibitor of DYRK1A, DYRK2, CLK1, and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 muM, respectively). | benzodioxoles; imidazolone; substituted aniline | autophagy inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.12.1 (dual-specificity kinase) inhibitor; neuroprotective agent; nootropic agent |